$Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience$

Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience

Background: We report our experience of patients with generalised myasthenia gravis (gMG) treated with efgartigimod, an neonatal Fc receptor antagonist, under the Early Access to Medicine Scheme (EAMS) in the UK. Methods: Data from all UK patients treated with efgartigimod under the EAMS July 2022 t...

Full description

Bibliographic Details
Main Authors:	Moniz Dionísio, J, Ambrose, P, Burke, G, Farrugia, ME, Garcia-Reitboeck, P, Hewamadduma, C, Hill, M, Howard, RS, Jacob, S, Kullmann, D, Leite, MI, Miller, J, Pinto, A, Pritchard, J, Riswick, T, Sathasivam, S, Thambirajah, N, Viegas, S, Norwood, F, Spillane, J
Format:	Journal article
Language:	English
Published:	BMJ Publishing Group 2025

Efgartigimod efficacy and safety in refractory myasthenia gravis: UK’s first real-world experience

Similar Items